References
- Akira S, Takeda K (2004). Toll-like receptor signalling. Nat Rev Immunol, 4, 499-511. https://doi.org/10.1038/nri1391
- Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. Cell, 124, 783-01. https://doi.org/10.1016/j.cell.2006.02.015
- Cohen J (2005). Pubic health High hopes and dilemmas for a cervical cancer vaccine. Science, 308, 618-21. https://doi.org/10.1126/science.308.5722.618
- Clifford GM, Smith JS, Plummer M, et al (2003). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 88, 63-73. https://doi.org/10.1038/sj.bjc.6600688
- Dolganiuc A, Garcia C, Kodys K, et al (2006). Distinct Toll-like receptor expression in monocytes and T cells in chronic HCV infection. World J Gastroenterol, 12, 1198-04.
- Daud II, Scott ME, Ma Y, et al (2011). Association between tolllike receptor expression and human papillomavirus type 16 persistence. Int J Cancer, 128, 879-86. https://doi.org/10.1002/ijc.25400
- Ferlay J, Autier P, Boniol M, et al (2007). Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol, 18, 581-92.
- Frisch M, Biggar RJ, Goedert JJ (2000). Human papillomavirusassociated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst, 92, 1500-10. https://doi.org/10.1093/jnci/92.18.1500
- Groskreutz DJ, Monick MM, Powers LS, et al (2006). Respiratory syncytial virus induces TLR3 protein and protein kinase R: leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol, 176, 1733-40. https://doi.org/10.4049/jimmunol.176.3.1733
- Huang B, Zhao J, Unkeless JC, et al (2008). TLR signaling by tumor and immune cells: a double-edged sword. Oncogene, 27, 218-24. https://doi.org/10.1038/sj.onc.1210904
- Horsmans Y, Berg T, Desager JP, et al (2005). Isatoribine an agonist of TLR7: reduces plasma virus concentration in chronic hepatitis C infection. Hepatology, 42, 724-31. https://doi.org/10.1002/hep.20839
- Hasan UA, Bates E, Takeshita F, et al (2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol, 178, 3186-97. https://doi.org/10.4049/jimmunol.178.5.3186
- IIvesaro JM, Merrell MA, Swain TM, et al (2007). Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 67, 774-81. https://doi.org/10.1002/pros.20562
- Krieg AM (2008). Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene, 27, 161-7. https://doi.org/10.1038/sj.onc.1210911
- Kim WY, Lee JW, Choi JJ, et al (2008). Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer, 18, 300-5. https://doi.org/10.1111/j.1525-1438.2007.01008.x
- LIU KJ, LIU JW, LI XR, et al (2008). Epidemiology study of risk factors on Uigur and Han cervical cancer in Xinjiang (J). J Xinjiang Med Univ, 31, 1335-8.
- Lenert PS (2010). Classification, mechanisms of action and therapeutic applications of inhibitory oligonucleotides for toll-like receptors (TLR) 7 and 9. Mediators Inflamm, 2010, 986596.
- Lee JW, Choi JJ, Seo ES, et al (2007). Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog, 46, 941-7. https://doi.org/10.1002/mc.20325
- Matijevic T, Pavelic J (2010). Toll-like receptors: cost or benefit for cancer. Curr Pharm, 16, 1081-90. https://doi.org/10.2174/138161210790963779
- Mishra A, Bharti AC, Varghese P, et al (2006). Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer, 119, 2840-50. https://doi.org/10.1002/ijc.22262
- Mukherjee S, Siddiqui MA, Dayal S, et al (2014). Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells. J Inflamm Res, 17, 89-101.
- Nees M, Geoghegan JM, Hyman T, et al (2001). Papillomavirus type 16 oncogenes down-regulate expression of interferonresponsive genes and up-regulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol, 75, 4283-96. https://doi.org/10.1128/JVI.75.9.4283-4296.2001
- Ostor AG (1993). Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol, 12, 186-92. https://doi.org/10.1097/00004347-199304000-00018
- Ren T, Wen ZK, Liu ZM, et al (2007). Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther, 6, 1704-9. https://doi.org/10.4161/cbt.6.11.4826
- Stanley MA, Pett MR, Coleman N (2007). HPV: from infection to cancer. Biochem Soc Trans, 35, 1456-60. https://doi.org/10.1042/BST0351456
- Sato Y, Goto Y, Narita N, et al (2009). Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron, 2, 205-14. https://doi.org/10.1007/s12307-009-0022-y
- Suzuke L, Peng YH, Zhou K, et al (2006). The analysis of pathogenetic tendency of cervical cancer in various ethnic women in Xinjiang. J Xinjiang Med Univ, 29, 569-71.
- Tezcan S, Ozgur D, Ulger M, et al (2014). Human papillomavirus genotype distribution and E6/ E7 oncogene expression in Turkish women with cervical cytological findings. Asian Pac J Cancer Prev, 15, 3997-4003. https://doi.org/10.7314/APJCP.2014.15.9.3997
- Tommasino M (2001). Early genes of human papillomaviruses: In Encyclopedic Reference of Cancer. Springer-Verlag, Heidelberg, 262-272.
- Takeshita F, Gursel I, Ishii KJ, et al (2004). Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol, 16, 17-22. https://doi.org/10.1016/j.smim.2003.10.009
- Takeshita F, Suzuki K, Sasaki S, et al (2004). Transcriptional regulation of the human TLR9 gene. J Immunol, 173, 2552-61. https://doi.org/10.4049/jimmunol.173.4.2552
- Wu XM, Liu X, Jiao QF, et al (2014). Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells. Asian Pac J Cancer Prev, 15, 2447-51. https://doi.org/10.7314/APJCP.2014.15.6.2447
- Wang D, Xiao PL, Duan HX, et al (2012). Peptidoglycans Promotes Human Leukemic THP-1 Cell Apoptosis and Differentiation. Asian Pacific J Cancer Prev, 13, 6409-13. https://doi.org/10.7314/APJCP.2012.13.12.6409
- Yang BH, Bray FI, Parkin DM, et al (2004). Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer, 109, 418-24. https://doi.org/10.1002/ijc.11719
- Wang D, Xiao PL, Duan HX, et al (2012). Lack of association of three common polymorphisms in Toll-like receptors (TLRs), TLR2+597T>C, +1350C>T and Arg753Gln with cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 14, 5871-76. https://doi.org/10.7314/APJCP.2013.14.10.5871
- Zhang GQ, LIU KJ, Lai XJ, et al (2003). Distribution of malignant tumor patients in hospital from 1989 to 2002 in the Affiliated Tumor Hospital of Xinjiang Medical University. J Xinjiang Med Univ, 26, 393-5.
- Zhang SQ, Yakup K, Abliz G, et al (2009). The study of the relationships between HPV multiple infection and cervical cancer of Uygur Women in Xinjiang. J Xinjiang Med Univ, 32, 525-8.
Cited by
- TLR9 gene polymorphism −1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population vol.143, pp.12, 2017, https://doi.org/10.1007/s00432-017-2495-2
- The Associations between Toll-Like Receptor 9 Gene Polymorphisms and Cervical Cancer Susceptibility vol.2018, pp.1466-1861, 2018, https://doi.org/10.1155/2018/9127146
- Therapeutic potential of toll‐like receptors in treatment of gynecological cancers pp.1521-6551, 2019, https://doi.org/10.1002/iub.2011